Paras Healthcare
Listing performance
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Subscription
- Qualified institutionalQIB
- 3.25×
- Big non-institutionalbNII · above ₹10 lakh
- 0.62×
- Small non-institutionalsNII · ₹2–10 lakh
- 0.84×
- Retail individualRII · up to ₹2 lakh
- 2.00×
Bids received
The demand behind each multiple — what was offered, what was bid for, and what those bids are worth
| Category | Shares offered | Shares bid for | Bids (₹ Cr) | Times |
|---|---|---|---|---|
| Qualified institutional | 62,77,056 | 2,03,81,592 | ₹1,412 Cr | 3.25× |
| Non-institutional | 31,38,528 | 21,66,213 | ₹150 Cr | 0.69× |
| Big non-institutionalwithin NII | 20,92,352 | 12,89,883 | ₹89.39 Cr | 0.62× |
| Small non-institutionalwithin NII | 10,46,176 | 8,76,330 | ₹60.73 Cr | 0.84× |
| Total | 1,15,07,936 | 2,69,43,315 | ₹1,867 Cr | 2.34× |
Times subscribed is the figure published for each category, not shares bid for divided by shares offered — a category's multiple is struck against its own allottable base, which is not always the offered count shown beside it. Observed 23 Oct, 05:11 pm IST; the registrar publishes the final basis of allotment.
Issue details
- IPO date
- 21 Oct 2026 – 23 Oct 2026
- Listing date
- 28 Oct 2026
- Face value
- ₹1 per share
- Price band
- ₹660 – ₹693
- Issue price
- ₹693 per share
- Lot size
- 21 shares
- Sale type
- Fresh capital cum OFS
- Issue type
- Book Building issue
- Listing at
- NSE
- Total issue size
- ₹1,450 Cr
- Fresh issue
- ₹500 Cr 72,15,007 shares
- Offer for sale
- ₹950 Cr 1,37,08,513 shares
- Market cap at offer price
- ₹7,498 Cr
- Promoter holding
- 72.80% → 63.95% pre-issue → post-issue
- ISIN
- INE661T01029
- CIN
- U85110HR1987PLC035823
- Registrar
- MUFG Intime India Pvt.Ltd.
- Lead managers
- JM Financial Ltd.
- Registered office
- 1st Floor, Tower B, Paras Twin Towers, Golf Course Road, Sector 54, Gurugram – 122 002, Haryana, India
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| QIB | 65,90,908 | 54.55% | 54.55% |
| Anchor investor · within QIB | 94,15,584 | — | 77.92% |
| NII (HNI) | 32,95,454 | 27.27% | 27.27% |
| bNII > ₹10L · within NII | 21,96,970 | — | 18.18% |
| sNII < ₹10L · within NII | 10,98,484 | — | 9.09% |
| Retail (RII) | 21,96,969 | 18.18% | 18.18% |
| Employee | 0 | — | 0.00% |
| Total issue | 1,20,83,331 | — | 100.00% |
Net offer to the public of 1,20,83,331 shares, out of a total issue of 1,20,83,331. Indented rows sit inside the category above them and are not added to it.
Application size
Minimum 21 shares per lot, in multiples, at ₹693
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 21 | ₹14,553 |
| Retail (max) | 13 | 273 | ₹1,89,189 |
| S-HNI (min) | 14 | 294 | ₹2,03,742 |
| S-HNI (max) | 68 | 1,428 | ₹9,89,604 |
| B-HNI (min) | 69 | 1,449 | ₹10,04,157 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Valuation and performance
Valuation at offer price
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 4.34 | 18.37 |
| P/E (×) | 159.68 | 37.72 |
| Price to book (×) | 17.72 | — |
| Market cap | — | ₹7,498 Cr |
Key performance indicators
- Return on net worth
- 12.98%
- ROCE
- 12.00%
- Debt / equity
- 3.53
- PAT margin
- 2.69%
- EBITDA margin
- 20.60%
- NAV per share
- ₹39.11
- Price to book
- 17.72
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
Company financials
| Period ended | FY26 | FY25 | FY24 |
|---|---|---|---|
| Profit and loss | |||
| Total income | 1,628.78 | 1,314.21 | 1,151.02 |
| Revenue from operations | 1,605.95 | 1,294.06 | 1,129.04 |
| Other income | 22.83 | 20.14 | 21.98 |
| Total expenses | 1,552.75 | 1,364.24 | 1,144.39 |
| Operating profit | 76.03 | -50.03 | 6.63 |
| Operating margin | 4.67% | -3.81% | 0.58% |
| Profit before tax | 76.03 | -50.04 | 6.63 |
| Profit after tax | 43.83 | -57.98 | -15.33 |
| PAT margin | 2.69% | -4.41% | -1.33% |
| Balance sheet | |||
| Total assets | 2,071.14 | 1,810.45 | 1,477.66 |
| Current assets | 774.89 | 517.72 | 373.63 |
| Current liabilities | 718.42 | 619.43 | 420.99 |
| Total liabilities | 1,676.2 | 1,529.96 | 1,139.15 |
| Net worth | 394.94 | 280.49 | 338.51 |
| Current ratio | 1.08× | 0.84× | 0.89× |
| Return on equity | 11.10% | -20.67% | -4.53% |
| Cash flow | |||
| Operating cash flow | 163.51 | 86.19 | 92.48 |
| Investing cash flow | -239.41 | -147.25 | -194.06 |
| Financing cash flow | 85.89 | 82.82 | 93.98 |
| Net cash flow | 9.99 | 21.76 | -7.6 |
Objects of the issue
1 Prepayment or Scheduled Re-payment of Outstanding Borrowings of the Company ₹321 Cr
The company intends to utilize a portion of the Net Proceeds towards prepayment or scheduled re-payment, in full or part, of certain outstanding borrowings availed by the company, including accrued interest and prepayment charges, to reduce overall indebtedness and improve debt-equity ratio.
2 Investment in Wholly Owned Subsidiary PMHPL for Repayment/Prepayment of Borrowings ₹54.10 Cr
The company proposes to invest in its wholly owned subsidiary, PMHPL (which also operates the hospital in Srinagar), through debt, to repay or prepay in full or part certain borrowings availed by PMHPL, thereby reducing consolidated indebtedness and improving the debt-equity ratio.
3 General Corporate Purposes —
The balance Net Proceeds, not exceeding a specified percentage of Gross Proceeds as per SEBI ICDR Regulations, are intended to be deployed towards general corporate purposes including organic and inorganic growth, capital expenditure, marketing, working capital, and business development initiatives.
1 of 3 objects carry no stated amount — typically general corporate purposes, funded from whatever remains — so the total above is the quantified portion only, not the whole issue.
About Paras Healthcare
Paras Healthcare Limited was incorporated on December 21, 1987 as 'Arbian Frozen Foods Private Limited' under the Companies Act, 1956. Its name was changed to 'Paras Healthcare Private Limited' in 2003 to reflect the change in business activity from frozen foods to healthcare services. The company converted to a public company in 2024 and its name was changed again in 2025. Its registered and corporate office is in Gurugram, Haryana. The company operates eight hospitals, including the Gurugram, Panchkula, Udaipur, Srinagar and Kanpur hospitals in North India and the Patna, Darbhanga and Ranchi hospitals outside North India. Two subsidiaries, Paras Healthcare (Ranchi) Private Limited and Plus Medicare Hospitals Private Limited, operate some of these hospitals. Revenue from operations comes from in-patient and out-patient healthcare services, sale of pharmacy products, and other operating revenue. Revenue from operations was ₹ 16,059.52 million in Fiscal 2026, and the CONGOR specialties contributed 74.70% of it. Patients pay through self-pay, insurance or third-party administrators, or government schemes.
Management
Dr. Dharminder Kumar Nagar
MD
Dr. Kapil Garg
Director
Strengths
As stated in the offer document
One of the Largest Healthcare Providers in North India, Bihar and Jharkhand with a First Mover Advantage and a Well-Recognized Brand
The company is one of the largest healthcare providers in North India, Bihar and Jharkhand with 2,211 beds across 8 hospitals as of June 30, 2026, holding first-mover positions in key markets such as Gurugram, Patna, Panchkula, Srinagar, and Kanpur, with a patient satisfaction score of 90.60 and net promoter score of 93.31 as of March 31, 2026.
Strong Focus on Tertiary and Quaternary Care with High Contribution from CONGOR Specialties
The company's hospitals are designed to deliver high-acuity tertiary and quaternary care, with CONGOR specialties (cardiac, oncology, neuro, gastro, orthopedics, renal sciences) contributing 74.35%, 75.30%, 74.70%, 71.92%, and 72.34% of revenue from operations in Q1 FY27, Q1 FY26, and Fiscals 2026, 2025, and 2024, respectively, supported by 559 ICU beds as of June 30, 2026.
Capital-Efficient and Flexible Operating Model with Disciplined Expansion
The company operates hospitals through a calibrated mix of owned, leased, revenue-sharing, and public-private partnership models, enabling lower upfront capital intensity and faster market entry; capital expenditure per bed stood at ₹7.70 million as of June 30, 2026, reflecting an efficient hospital design philosophy.
Delivering High-Quality Clinical Care Through Renowned Clinicians, Supported with Modern Equipment
The company's clinical model is anchored by 1,084 doctors and 1,937 nurses as of June 30, 2026, including 3 Padma Shri awardees, supported by advanced equipment such as biplane cath labs, LINACs, surgical robots, and PET-CT scanners, with DNB/DrNB programs training up to 60 students annually across 14 specialties.
Digital Technology Enabling Clinical Effectiveness, Patient Experience and Operational Efficiencies
The company has established a cloud-first digital ecosystem comprising an omni-channel patient experience platform, integrated EHR system, doctor mobile application, and business intelligence platforms integrated with HIS and ERP systems, enhancing scalability, agility, and operational efficiency across the hospital network.
Doctor-Led Professional Management Team with Proven Execution Capabilities
The company's management is led by Dr. Dharminder Kumar Nagar (22+ years of healthcare experience) alongside a senior team with deep functional expertise, including a CFO with 38+ years of experience and a COO with 22+ years of experience, collectively driving a revenue CAGR of 19.26% from Fiscal 2024 to Fiscal 2026.
Risk factors
As stated in the offer document
History of Losses and Uncertain Profitability
The company incurred consolidated losses of ₹(10.24) million, ₹(579.83) million, and ₹(153.31) million in Q1 FY2026, FY2025, and FY2024, respectively, primarily due to ramp-up costs at new hospitals. The company had the lowest RoCE and RoE and the highest debt-to-equity ratio compared to listed peers, and cannot assure sustained profitability going forward.
Substantial Indebtedness and Debt Service Obligations
As of August 31, 2026, the company's outstanding fund-based borrowings on a consolidated basis were ₹9,394.67 million, with finance costs of ₹1,159.78 million in FY2026. The interest coverage ratio declined to 0.75x in FY2025, and any inability to service debt or comply with financial covenants could materially adversely affect operations and financial condition.
High Attrition Rates of Healthcare Professionals
The company experienced overall attrition rates of 60.38%, 66.74%, and 65.27% in FY2026, FY2025, and FY2024, respectively, with retainers and consultants fees alone accounting for ~25% of total expenses. Inability to attract and retain qualified doctors, nurses, and healthcare professionals could impair service quality, occupancy levels, and revenue generation.
Geographic Concentration Risk in North India
Five of the company's eight hospitals are located in North India, contributing approximately 66–68% of revenue from operations across recent periods. This concentration exposes the company to regional risks including adverse economic conditions, regulatory changes, natural disasters, and security incidents such as the April 2025 Pahalgam terror attack that briefly disrupted Srinagar Hospital operations.
Revenue Concentration in CONGOR Specialties
The CONGOR specialties (cardiac, oncology, neuro, gastro, orthopedics, and renal sciences) contributed approximately 74.35%, 75.30%, and 74.70% of revenue from operations in Q1 FY2027, Q1 FY2026, and FY2026, respectively. Any reduction in demand, loss of key specialists, or increased competition in these specialties could have a disproportionate adverse impact on revenues and profitability.
High Operating Cost Structure and Inability to Pass on Cost Increases
Employee benefits, retainers/consultants fees, and stock-in-trade purchases collectively accounted for approximately 65–67% of total expenses across recent periods. A 1% increase across all three cost components would reduce FY2026 profit before tax by approximately 13.29%, and competitive and regulatory pricing constraints may prevent the company from passing cost increases to patients.
Dependence on Leased Hospital Premises with Unregistered Lease Deeds
Six of the company's eight hospitals operate on leased premises, contributing 60–61% of revenue from operations, with lease deeds for Panchkula, Darbhanga, Ranchi, and Srinagar hospitals being unregistered and thus of limited evidentiary value. Any termination, non-renewal, or adverse modification of these arrangements could severely disrupt hospital operations and financial performance.
Company Analysis
from RHPParas Healthcare Limited operates hospitals in India that provide healthcare services across cardiac, oncology, neuro, gastro, orthopedics and sports injury, and renal specialties.
Paras Healthcare Limited was incorporated on December 21, 1987 as 'Arbian Frozen Foods Private Limited' under the Companies Act, 1956. Its name was changed to 'Paras Healthcare Private Limited' in 2003 to reflect the change in business activity from frozen foods to healthcare services. The company converted to a public company in 2024 and its name was changed again in 2025. Its registered and corporate office is in Gurugram, Haryana. The company operates eight hospitals, including the Gurugram, Panchkula, Udaipur, Srinagar and Kanpur hospitals in North India and the Patna, Darbhanga and Ranchi hospitals outside North India. Two subsidiaries, Paras Healthcare (Ranchi) Private Limited and Plus Medicare Hospitals Private Limited, operate some of these hospitals. Revenue from operations comes from in-patient and out-patient healthcare services, sale of pharmacy products, and other operating revenue. Revenue from operations was ₹ 16,059.52 million in Fiscal 2026, and the CONGOR specialties contributed 74.70% of it. Patients pay through self-pay, insurance or third-party administrators, or government schemes.
Objects of the Issue
- Funding investment in PMHPL for repayment / prepayment of certain borrowings p.27
- Prepayment or scheduled repayment, in full or part, of certain outstanding borrowings availed by the Company 3,209.00 million p.124
- Investment in wholly owned Subsidiary PMHPL for repayment or prepayment of PMHPL's borrowings 541.00 million p.124
- General corporate purposes p.124
- Prepayment or scheduled re-payment, in full or part, of certain outstanding borrowings availed by the Company ₹ 3,209.00 million p.131
- Investment in wholly owned Subsidiary PMHPL for repayment/prepayment of PMHPL's borrowings, in full or part ₹ 541.00 million p.137
- General corporate purposes p.139
- Prepayment or scheduled repayment of all or a portion of the principal on certain loans availed by the Company, and the accrued interest thereon up to ₹ 3,209.00 million p.479
- Investment in subsidiary PMHPL to repay or prepay, in full or in part, its borrowings up to ₹ 541.00 million p.479
Issue Structure
- Total Issue
- up to ₹ 14,500.00 million
- Fresh Issue
- up to ₹ 5,000.00 million
- Offer for Sale
- up to ₹ 9,500.00 million
- Lot Size
- [●] Equity Shares and in multiples of [●] Equity Shares thereafter
- Face Value
- ₹ 1 per Equity Share
Business Model
The company earns revenue by providing in-patient and out-patient healthcare services at its hospitals and by selling pharmacy products. Other operating revenue is also included in revenue from operations. Patients pay directly (self-pay), through insurance or third-party administrators, or through government schemes and PSUs. Several hospitals operate on leased premises, under revenue share arrangements, long-term leases, or a public-private partnership.
Business Segments
SWOT Analysis
- • Well-recognized brand in North India(p.31)
- • Eight-hospital network with 2,211 total beds(p.30)
- • Revenue from operations growth across fiscal years(p.26)
- • Profitable in Fiscal 2026(p.27)
- • Large bed capacity across eight hospitals in North India, Bihar and Jharkhand(p.145)
- • Seven hospitals accredited by NABH(p.145)
- • High patient satisfaction and net promoter scores(p.145)
- • CONGOR specialties drive the majority of revenue(p.145)
- • Experienced clinical team including Padma Shri awardees(p.146)
- • Promoter-led hospital commissioning track record(p.146)
- • Cloud-first digital ecosystem supporting operations(p.146)
- • Auditor issued an unmodified opinion on the restated consolidated financial statements.(p.361)
- • No invocation of guarantees and no loan default in the past three Fiscals.(p.357)
- • Management-level attrition is stated to be lower than the industry average.(p.352)
- • Revenue from operations grew from INR 11,290.39 million (FY2024) to INR 16,059.52 million (FY2026).(p.367)
- • Eight-hospital network across five states and one union territory(p.438)
- • Mature Hospitals are a steady, substantial revenue base(p.439)
- • EBITDA improvement from operating leverage and fixed-cost absorption(p.439)
- • Mature hospitals show stable and rising occupancy and ARPOB despite competition(p.446)
- • Revenue spread across specialties, with no single specialty above 25% of revenue(p.446)
- • No dependence on a single or few customers; no external customer at 10% or more of revenue(p.484)
- • Average length of stay optimised through clinical and bed-management measures(p.446)
- • Operating cash generation rose to ₹1,635.12 million in Fiscal 2026 from ₹861.91 million in Fiscal 2025(p.476)
- • Losses in recent periods; lowest RoCE and RoE among listed peers(p.26)
- • Subsidiaries loss-making while scaling hospitals(p.27)
- • High staff attrition rates(p.27)
- • Concentration of hospitals in North India(p.30)
- • Majority of hospitals on leased premises, some unregistered deeds(p.33)
- • Contingent liabilities at 89.55% of net worth(p.36)
- • Outstanding litigation against Company, subsidiaries, promoter and directors(p.37)
- • Promoter Group member listed in CIBIL wilful defaulter database(p.31)
- • Substantial indebtedness requires significant cash flows to service and limits operating flexibility(p.48)
- • Subsidiaries PHRPL and PMHPL have reported negative net worth(p.55)
- • Past suspensions and temporary restrictions on government health scheme empanelments(p.39)
- • Criminal complaint against Promoter and Managing Director relating to a patient case(p.39)
- • History of delays in commencing operations at new hospitals(p.40)
- • Bed occupancy rate declined between Fiscal 2024 and Fiscal 2025(p.44)
- • Long payment cycles from government schemes and PSUs drive receivables(p.47)
- • Promoter will hold majority and substantial control post-Offer(p.65)
- • Contingent liabilities equal 89.55% of net worth as of June 30, 2026.(p.91)
- • Quarterly results may fluctuate and may not be meaningful for period-to-period comparison.(p.74)
- • No assurance of sufficient revenue to pay dividends; none declared in the last three Fiscals or the three months to June 30, 2026.(p.74)
- • Some historical corporate filings (Form-2 challans) cannot be traced by the company.(p.108)
- • High existing borrowings, with debt-equity of 2.00 times as at June 30, 2026(p.139)
- • Prior credit rating watch and downgrade, with risk of higher borrowing costs(p.139)
- • Scale existing hospitals and expand network in North India(p.27)
- • Proposed hospital pipeline in Gurugram(p.7)
- • Fragmented North India hospital sector with low private chain share(p.40)
- • Bed shortfall versus NHP-recommended levels in North India and Bihar/Jharkhand(p.40)
- • Plan to expand network in North India markets with growth potential(p.40)
- • Planned increase in bed capacity from 2,211 to 3,011 by March 2028(p.40)
- • Growth strategy to expand beds in existing hospitals and add new hospitals(p.45)
- • Net Proceeds planned for prepayment or repayment of existing company borrowings (₹3,209.00 million estimated).(p.129)
- • Company expects listing to enhance visibility, brand image and create a public market for its shares.(p.129)
- • Lower debt-equity may enable cheaper future fundraising for expansion(p.131)
- • Residual proceeds earmarked for organic and inorganic growth(p.139)
- • Emerging and New Hospitals identified as key growth drivers in early ramp-up(p.438)
- • Empanelment under CGHS, ECHS and insurance schemes adding revenue at new hospitals(p.439)
- • Expansion into oncology services at Ranchi and Udaipur via LINAC installation(p.439)
- • Bed capacity planned to rise from 2,211 to 3,011 through Gurugram and Ludhiana hospitals(p.445)
- • Mature hospitals have headroom via higher share of government-scheme patients and shift toward insurance and self-pay(p.446)
- • Shifting payor mix toward private insurance and self-pay may improve realizations(p.446)
- • Scale benefits from centralised procurement and shared administrative functions(p.445)
- • Use of Net Proceeds to repay borrowings is expected to cut finance costs(p.475)
- • Revised CGHS and ECHS package rates improved realizations from scheme-covered patients(p.449)
- • Regulatory and policy-driven price caps limit pass-through of costs(p.33)
- • Regional security and terror-related disruption in Jammu and Kashmir(p.31)
- • Competition for doctors from other hospital chains(p.28)
- • Industry shortage of specialised doctors(p.27)
- • Rising input and operating costs(p.32)
- • Rapid medical and technological change requires upgrades(p.32)
- • NPPA price caps and possible DPCO expansion limit pricing and margins(p.42)
- • Government push toward standardized hospital fee rates(p.43)
- • Competition from government and private hospitals and diagnostic chains(p.62)
- • Flood and water-logging exposure at hospitals near rivers and low-lying areas(p.63)
- • Labour Codes effective from November 2025 with state rules pending(p.43)
- • Data protection laws carry penalties up to specified amounts(p.43)
- • Infectious disease outbreaks could disrupt operations, patient volumes and supply chains.(p.75)
- • Slowdown in the Indian economy or its sectors could reduce business performance.(p.75)
- • Sovereign rating changes could raise borrowing costs and limit financing access.(p.76)
- • Competition Act application may affect agreements and future acquisitions; impact cannot be predicted.(p.76)
- • New Labour Codes may raise employee and labour costs across clinical and support staff.(p.77)
- • Unresolved GST treatment of in-patient medicines and consumables could create retrospective tax liabilities.(p.77)
- • Inflation may raise costs faster than the company can pass them on to customers.(p.78)
- • Fund deployment exposed to interest rate and other external factors outside management control(p.130)
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Dr. Dharminder Kumar Nagar | Promoter | — | — |
| Harbaksh Singh Khangura | Promoter Group | — | — |
| Dr. Dharminder Kumar Nagar | Promoter | 72.80% | — |
| Dr. Dharminder Kumar Nagar | Promoter | 72.80% | — |
| Gurdeep Kaur Nagar; Ranya Nagar | Promoter Group | Negligible | — |
| Dr. Dharminder Kumar Nagar | Promoter | — | — |
| Dr. Dharminder Kumar Nagar | Promoter | 72.80% | — |
| Dr. Dharminder Kumar Nagar | Promoter | 72.80% | — |
| Dr. Dharminder Kumar Nagar | Promoter | 72.80% | — |
| Dr. Dharminder Kumar Nagar | Promoter | — | — |
| Dr. Dharminder Kumar Nagar | Promoter | — | — |
Leadership
Auto-extracted from the company's RHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official RHP before relying on it.
Peer comparison
| Company | EPS | NAV | P/E | P/BV | RoNW |
|---|---|---|---|---|---|
| Paras Healthcare Ltd. THIS ISSUE | 4.34 | 39.11 | 37.72, computed at the offer price | 17.72, computed at the offer price | 12.98% |
| 7.53 | 88.32 | 91.89 | 7.85 | 9.70% | |
| 135.04 | 657.58 | 59.36 | 12.19 | 21.95% | |
| 13.80 | 131.07 | 55.43 | 5.84 | 11.08% | |
| 20.71 | 147.06 | 64.46 | 9.05 | 15.15% | |
Jupiter Lifeline Hospitals Ltd. | 5.92 | 47.10 | 42.92 | 5.40 | 13.41% |
| 6.03 | 56.17 | 116.41 | 12.52 | 11.01% | |
| 7.71 | 63.26 | 87.00 | 10.59 | 12.37% | |
| 14.83 | 109.53 | 62.10 | 8.40 | 14.33% | |
| 39.67 | 222.02 | 43.41 | 7.75 | 19.74% | |
| 18.20 | 184.79 | 55.16 | 5.45 | 10.36% |
Blank cells are figures the offer document does not publish. This issue is unlisted, so it has no market price and the document publishes no multiple for it — its P/E and P/BV here are computed at the offer price, on the post-issue share count, and are comparable to a listed peer's.